New research has introduced a strategy that could considerably reduce the need for insulin therapy in patients with type 2 diabetes (T2D)

For hundreds of millions worldwide, diabetes is not just a physical condition, it’s an around-the-clock emotional challenge. Hearing from advocates around the world ahead of World Diabetes Day, it’s clear this burden is shared across the entire diabetes community. Our advocate from Zimbabwe described the constant vigilance and decision-making required to manage his condition, while in Spain they reflected on the unchosen limitations diabetes places on daily life. In India, another advocate highlighted the intense mental strain of balancing work, rest and nutrition. These experiences reveal how daily diabetes management imposes a hidden burden on mental well-being, which is largely unseen by society and unaddressed by healthcare systems.

MACE reduction was a key finding in the topline results from the Semaglutide Cardiovascular Outcomes Trial (SOUL), which reported that oral semaglutide, a long-acting Glucagon-Like Peptide-1 (GLP-1) receptor agonist, significantly decreases the risk of major adverse cardiovascular events in adults with type 2 diabetes (T2D) who have established atherosclerotic cardiovascular disease (ASCVD) and/or chronic kidney disease (CKD).

touchENDOCRINOLOGY was delighted to speak with Editorial Board member Dr Deep Dutta, a senior endocrinologist at the CEDAR Superspecialty Clinics, New Delhi, India. Throughout this interview, he summarizes the key messages from his late-breaking abstract session ‘Ailing Heart, Broken Vessels’, presented at the 60th European Association for the Study of Diabetes (EASD) annual meeting in Madrid, Spain.

In this expert Q&A we are delighted to welcome our Editorial Board member Dr Sanjay Kalra, a leading endocrinologist with over two decades of experience at Bharti Hospital, Karnal, India. A passionate educator and researcher, Dr Kalra serves as Education Editor of the International Society of Endocrinology (ISE) and is deeply involved in global endocrine education. His leadership extends to roles such as Immediate Past President of the Endocrine Society of India and Vice-President of the South Asian Federation of Endocrine Societies.

Olaf Dekkers highlights this new European Society of Endocrinology and Endocrine Society Joint Clinical Guideline,1 the first of many future collaborations

Established more than 25 years ago, the Immunology of Diabetes Society (IDS) is dedicated to improving our understanding of the mechanisms by which the immune system and the pancreas contribute to the development of type 1 diabetes (T1D). Every 18 months, the ...

Tthe American Association of Clinical Endocrinology (AACE) is a global, inclusive community of endocrine-focused members and stakeholders from diverse professional backgrounds.

We're looking forward to the 60th anniversary of the EASD Annual Meeting 2024, which is taking place in Madrid between 9-13 September 2024. Promising attendees an opportunity to explore the latest technologies, treatments, and products in the field of diabetes, we are ...